ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension
Laura M. Gault(AbbVie (United States)), Weining Robieson(AbbVie (United States)), Yili Pritchett(Abbott (United Kingdom)), Qi Tang(AbbVie (United States)), Ahmed A. Othman(Gilead Sciences (United States)), Andreas Meier(Pfizer (United States)), Scott Berry(Queen's University), Robert Lenz(Amgen (United States)), Craig Ritchie(Western General Hospital)
Cited by 39
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818